The BVA-100 (Blood Volume Analyzer) is a revolutionary instrument, developed by DAXOR Corporation and approved by the FDA, to precisely measure blood volume in the human body.

Read More

Key Features

  • Superior  blood volume measurement
  • Results in under 1 hour
  • Clinically proven — significant survival benefits

Latest News

Daxor Corporation Announces Filing of Form N-CSR for December 31, 2014

(NYSE MKT LLC: DXR) New York, NY, February 27, 2015 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of December 31, 2014. Copies of the form will be mailed to the Company’s shareholders and […]

Read More

Daxor Corporation Announces Major Research Studies

Major Research Presented and Published at the Critical Care Congress in Phoenix, Arizona, Utilizing the Daxor BVA-100 Blood Volume Analyzer A study on 50 patients with severe sepsis published in the journal Critical Care Medicine, Volume 42, No.12, December 2014, entitled Central Venous Pressure: Is It An Accurate Reflection of Intravascular Volume Status? analyzed whether central venous […]

Read More


“BVA allows physicians to determine an accurate status on heart failure patients.”

Shamsuddin Khwaja
Cardiothoracic Surgeon
Fresno Heart and Surgical Hospital

“We are excited to have acquired the blood volume analyzer. We see this as a valuable tool for guiding therapy for our heart failure patients.”

Dr. Gamal Sidarous, Nuclear Medicine Physician at Banner Good Samaritan Medical Center 

“I view this as an opportunity to improve patient outcomes for those associated with poor prognosis.  I believe that this advanced testing method will become an essential service in treating heart failure and other life threatening conditions.”

Max Akin, president of North Alabama RadioPharmacy